Single Dose Of Sputnik V Vaccine Triggers Strong Antibody Re
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
A single dose of the Sputnik V vaccine may be enough to elicit strong antibody response against SARS-CoV-2, in already infected people, according to a study. The new study, examined whether a single dose would achieve greater public health benefit than two doses by allowing protection of a larger population more quickly.

In the latest study, the researchers compared the effects of one and two shots of Sputnik V on SARS-CoV-2-specific antibody responses in 289 healthcare workers in Argentina. Three weeks after the second dose, all volunteers with no prior infection generated virus-specific immunoglobulin G (IgG) antibodies -- the most common type of antibody found in blood.

However, even within three weeks of receiving the first dose, 94 percent of these participants developed IgG antibodies against the virus, and 90 percent showed evidence of neutralising antibodies, which interfere with the ability of viruses to infect cells. The research further showed that IgG and neutralising antibody levels in previously infected participants were significantly higher after one dose than those in fully vaccinated volunteers with no history of infection.

A second dose did not increase the production of neutralising antibodies in previously infected volunteers. "This highlights the robust response to vaccination of previously infected individuals, suggesting that naturally acquired immunity might be enhanced sufficiently by a single dose, in agreement with recent studies using mRNA vaccines," researcher said.

The researchers noted that further studies are needed to evaluate the duration of the immune response and to assess how antibody levels relate to vaccine protection against COVID-19. The high antibody levels after a single dose in naive participants suggests a benefit of delaying second dose administration to increase the number of people vaccinated, they said.

Source:
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00208-1#relatedArticles
Dr. T●●●●z H●●●●●●i and 4 others like this8 shares
Like
Comment
Share